TICKERNERD
Menu
IKTIKTHealthcare · Biotechnology

IKT Stock Forecast: Inhibikase Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.91
−1.55% on the day

The 9 Wall Street analysts covering Inhibikase Therapeutics, Inc. hold a median 12-month price target of $6 — +214.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$276.3M
Ticker Nerd rank
40 / 100
Median analyst target
$6.00
Analysts covering
9
Revenue$0.0
Operating income−$21.1M
Net income−$19.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
−21.4%
YTD
−6.8%
1Y
+15.1%
From 52W high
−24.2%
From 52W low
+35.5%
$1.41
$2.52
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IKT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Inhibikase Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
76
Volatility
64
Size
63
Quality
63
Revisions
40
Growth
39
Accruals
36
Value
35
Issuance
27

Momentum (76): The shares have been drifting up relative to others.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IKT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IKT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26IKTHigh $8.00Median $6.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $3.00Median $6.00High $8.00

The green dot is the last close — the median target sits +214.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 June 2026OppenheimerInitiatesOutperform$5.00
4 Mar 2026Ladenburg ThalmannInitiatesBuy—
21 Jan 2026B of A SecuritiesInitiatesBuy—
26 Dec 2025HC Wainwright & Co.AssumesBuy$8.00
17 Dec 2025Freedom BrokerInitiatesBuy—
11 Dec 2025Cantor FitzgeraldInitiatesOverweight—
28 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
12 Feb 2025HC Wainwright & Co.DowngradeNeutral—
8 Nov 2024JefferiesInitiatesBuy—
14 Oct 2024HC Wainwright & Co.MaintainsBuy—
16 Aug 2024HC Wainwright & Co.MaintainsBuy—
21 May 2024HC Wainwright & Co.MaintainsBuy—
7 Mar 2024HC Wainwright & Co.ReiteratesBuy—
5 Mar 2024HC Wainwright & Co.MaintainsBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
30 June 2023HC Wainwright & Co.MaintainsBuy—
22 June 2023HC Wainwright & Co.ReiteratesBuy$5.00
18 Apr 2023HC Wainwright & Co.InitiatesBuy$5.00
16 Nov 2022JonesTradingDowngradeHold—
15 July 2021JonesTradingInitiatesBuy$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IKT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IKT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Inhibikase Therapeutics, Inc. returned +15.1% against +16.2% for the S&P 500, dividends included.

IKT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26IKTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IKT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Inhibikase Therapeutics, Inc. (IKT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.6×

Cheaper than 67% of US stocks

Price / sales
—
Price / book
2.3×

Cheaper than 40% of US stocks

EV / EBITDA
−3.0×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−52.0%

Higher than 21% of US stocks

Return on assets
−32.8%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Inhibikase Therapeutics, Inc. (IKT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Inhibikase Therapeutics, Inc. has a market value of $276.3M and an enterprise value of $201.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$60.6M.

  • Shares outstanding: 157.0M.

  • Trailing P/E: 3.6×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Inhibikase Therapeutics, Inc. employs 35 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

IKT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IKTInhibikase Therapeutics, Inc.$276.3M
40
VNDAVanda Pharmaceuticals, Inc.$267.8M
47
SABSSAB Biotherapeutics, Inc.$263.0M
39
IPSCCentury Therapeutics, Inc.$262.3M
38
VOGXVogenx, Inc.$259.8M
2
ACIUAC Immune SA$259.5M
33
BBOTBridgebio Oncology Therapeutics, Inc.$274.2M
7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Inhibikase Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IKT news & analysis

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

Inhibikase Therapeutics announced it granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of common stock to two newly-hired non-executive employees under its 2026 Inducement Equity Plan, effective September 30, 2026. The grants were approved by the Compensation Committee as a material inducement to the employees' entry into employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — IKT watchers would care because this discloses new shareholder-dilutive equity compensation tied to recent hires, and confirms the company is expanding headcount under its inducement plan.

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

GlobeNewsWire · 11 Aug 2026neutral

Inhibikase Therapeutics reported its financial results for the quarter ended June 30, 2026, and highlighted recent developments. The company, which is developing IKT-001 for Pulmonary Arterial Hypertension, announced these results via GlobeNewsWire on August 11, 2026.

Why it matters — IKT watchers would care because the quarterly financial results and recent activity update offer insight into the company's progress and cash position as it advances its PAH clinical program.

FAQ

Frequently asked questions about IKT stock

What is the IKT stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Inhibikase Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $3 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IKT stock a buy right now?

Of the 9 analysts covering Inhibikase Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inhibikase Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IKT?

As at 8 Oct 2026, Inhibikase Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (76 of 100).

Will IKT stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +214.1% from the last close, and Ticker Nerd's factor model ranks Inhibikase Therapeutics, Inc. 40 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IKT stock forecast for 2030?

No analyst covering Inhibikase Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8 over the next 12 months.

How has IKT stock performed over the past year?

Inhibikase Therapeutics, Inc. returned +15.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Inhibikase Therapeutics, Inc. do?

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapies for cardiopulmonary and neurodegenerative diseases.

What is the latest news on IKT?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Inhibikase Therapeutics announced it granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of common stock to two newly-hired non-executive employees under its 2026 Inducement Equity Plan, effective September 30, 2026. The grants were approved by the Compensation Committee as a material inducement to the employees' entry into employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapies for cardiopulmonary and neurodegenerative diseases. Its current portfolio is centered on pulmonary arterial hypertension, where it is advancing an oral prodrug of imatinib mesylate designed to address disease pathways linked to abnormal kinase signaling. The company also maintains a neuroscience-oriented program targeting Parkinson’s disease and related disorders through Abelson tyrosine kinase inhibition. Inhibikase Therapeutics works across areas of rare disease, cardiopulmonary medicine, and neurology, with a business model built around small-molecule drug development and clinical research. Headquartered in Wilmington, Delaware, Inhibikase Therapeutics plays a specialized role in the biopharmaceutical market by pursuing therapies for conditions with limited treatment options and significant unmet medical need.

CEO Mr. Mark T. Iwicki · 35 employees · United States · https://www.inhibikase.com